 | • レポートコード：MRC2307A0264 • 出版社/出版日：Transparency Market Research / 2023年4月 • レポート形態：英文、PDF、237ページ • 納品方法：Eメール • 産業分類：バイオ |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の市場調査資料によると、世界の間葉系幹細胞市場規模は2023年の32億ドルから2031年には101億ドルへ上り、予想期間中、年平均12.7％拡大すると予測されています。本調査資料では、間葉系幹細胞の世界市場を調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要洞察、製品・サービス別（製品、サービス）分析、種類別（自家、同種）分析、分離源別（骨髄、歯髄、その他）分析、疾患別（筋骨格系疾患、心血管疾患、神経疾患、自己免疫疾患、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などについて明らかにしています。なお、本書に記載されている企業情報には、Thermo Fisher Scientific, Inc.、Cytiva (Danaher Corporation)、FUJIFILM Irvine Scientific (FUJIFILM Corporation)、Merck KGaA、Lonza Group Ltd.、STEMCELL Technologies, Inc.、Takara Bio, Inc.、Sartorius AG、Miltenyi Biotec GmbH and、PromoCell GmbHなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要洞察 ・世界の間葉系幹細胞市場規模：製品・サービス別 - 製品の市場規模 - サービスの市場規模 ・世界の間葉系幹細胞市場規模：種類別 - 自家間葉系幹細胞の市場規模 - 同種間葉系幹細胞の市場規模 ・世界の間葉系幹細胞市場規模：分離源別 - 骨髄における市場規模 - 歯髄における市場規模 - その他分離源における市場規模 ・世界の間葉系幹細胞市場規模：疾患別 - 筋骨格系疾患における市場規模 - 心血管疾患における市場規模 - 神経疾患における市場規模 - 自己免疫疾患における市場規模 - その他疾患における市場規模 ・世界の間葉系幹細胞市場規模：地域別 - 北米の間葉系幹細胞市場規模 - ヨーロッパの間葉系幹細胞市場規模 - アジア太平洋の間葉系幹細胞市場規模 - 中南米の間葉系幹細胞市場規模 - 中東・アフリカの間葉系幹細胞市場規模 ・競争状況 |
Mesenchymal Stem Cells Market – Scope of Report
TMR’s report on the global Mesenchymal Stem Cells Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Mesenchymal Stem Cells Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Mesenchymal Stem Cells Market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.
The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Mesenchymal Stem Cells Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Mesenchymal Stem Cells Market profiled in this report.
Key Questions Answered in Global Mesenchymal Stem Cells Market Report
• What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
• What are the opportunities in the global Plasmonic Materials market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Mesenchymal Stem Cells Market – Research Objectives and Research Approach
The comprehensive report on the global Mesenchymal Stem Cells Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Mesenchymal Stem Cells Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Mesenchymal Stem Cells Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Mesenchymal Stem Cells Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List Of Major Research Institutes Involved In Mesenchymal Stem Cells Studies
5.3. Mesenchymal Stem Cells: Current Trends and Future Prospects in a Variety of Disease Conditions
5.4. Regulatory Scenario by Region/globally
5.5. COVID-19 Pandemic Impact on Industry
6. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Products & Services
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Products & Services, 2017–2031
6.3.1. Product
6.3.1.1. Workflow Type
6.3.1.2. Product Type
6.3.2. Services
6.4. Market Attractiveness Analysis, by Products & Services
7. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type, 2017–2031
7.3.1. Autologous
7.3.2. Allogenic
7.4. Market Attractiveness Analysis, by Type
8. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Source of Isolation
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Source of Isolation, 2017–2031
8.3.1. Bone Marrow
8.3.1.1. Adipose
8.3.1.2. Cord Blood
8.3.1.3. Peripheral Blood
8.3.2. Dental Pulp
8.3.3. Others (lung tissue, umbilical cord tissue, etc.)
8.4. Market Attractiveness Analysis, by Source of Isolation
9. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Indication, 2017–2031
9.3.1. Musculoskeletal Diseases
9.3.2. Cardiovascular Diseases
9.3.3. Neuro Disorders
9.3.4. Autoimmune Diseases
9.3.5. Cancer
9.3.6. GvHD
9.3.7. Pulmonary Diseases
9.3.8. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Mesenchymal Stem Cells Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Products & Services, 2017–2031
11.2.1. Product
11.2.1.1. Workflow Type
11.2.1.2. Product Type
11.2.2. Services
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Autologous
11.3.2. Allogenic
11.4. Market Value Forecast, by Source of Isolation, 2017–2031
11.4.1. Bone Marrow
11.4.1.1. Adipose
11.4.1.2. Cord Blood
11.4.1.3. Peripheral Blood
11.4.2. Dental Pulp
11.4.3. Others (lung tissue, umbilical cord tissue, etc.)
11.5. Market Value Forecast, by Indication , 2017–2031
11.5.1. Musculoskeletal Diseases
11.5.2. Cardiovascular Diseases
11.5.3. Neuro Disorders
11.5.4. Autoimmune Diseases
11.5.5. Cancer
11.5.6. GvHD
11.5.7. Pulmonary Diseases
11.5.8. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Type
11.7.3. By Source of Isolation
11.7.4. By Indication
11.7.5. By Country
12. Europe Mesenchymal Stem Cells Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Products & Services, 2017–2031
12.2.1. Product
12.2.1.1. Workflow Type
12.2.1.2. Product Type
12.2.2. Services
12.3. Market Value Forecast, by Type, 2017–2031
12.3.1. Autologous
12.3.2. Allogenic
12.4. Market Value Forecast, by Source of Isolation, 2017–2031
12.4.1. Bone Marrow
12.4.1.1. Adipose
12.4.1.2. Cord Blood
12.4.1.3. Peripheral Blood
12.4.2. Dental Pulp
12.4.3. Others (lung tissue, umbilical cord tissue, etc.)
12.5. Market Value Forecast, by Indication , 2017–2031
12.5.1. Musculoskeletal Diseases
12.5.2. Cardiovascular Diseases
12.5.3. Neuro Disorders
12.5.4. Autoimmune Diseases
12.5.5. Cancer
12.5.6. GvHD
12.5.7. Pulmonary Diseases
12.5.8. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Type
12.7.3. By Source of Isolation
12.7.4. By Indication
12.7.5. By Country/Sub-region
13. Asia Pacific Mesenchymal Stem Cells Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Products & Services, 2017–2031
13.2.1. Product
13.2.1.1. Workflow Type
13.2.1.2. Product Type
13.2.2. Services
13.3. Market Value Forecast, by Type, 2017–2031
13.3.1. Autologous
13.3.2. Allogenic
13.4. Market Value Forecast, by Source of Isolation, 2017–2031
13.4.1. Bone Marrow
13.4.1.1. Adipose
13.4.1.2. Cord Blood
13.4.1.3. Peripheral Blood
13.4.2. Dental Pulp
13.4.3. Others (lung tissue, umbilical cord tissue, etc.)
13.5. Market Value Forecast, by Indication , 2017–2031
13.5.1. Musculoskeletal Diseases
13.5.2. Cardiovascular Diseases
13.5.3. Neuro Disorders
13.5.4. Autoimmune Diseases
13.5.5. Cancer
13.5.6. GvHD
13.5.7. Pulmonary Diseases
13.5.8. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. South Korea
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Type
13.7.3. By Source of Isolation
13.7.4. By Indication
13.7.5. By Country/Sub-region
14. Latin America Mesenchymal Stem Cells Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Products & Services, 2017–2031
14.2.1. Product
14.2.1.1. Workflow Type
14.2.1.2. Product Type
14.2.2. Services
14.3. Market Value Forecast, by Type, 2017–2031
14.3.1. Autologous
14.3.2. Allogenic
14.4. Market Value Forecast, by Source of Isolation, 2017–2031
14.4.1. Bone Marrow
14.4.1.1. Adipose
14.4.1.2. Cord Blood
14.4.1.3. Peripheral Blood
14.4.2. Dental Pulp
14.4.3. Others (lung tissue, umbilical cord tissue, etc.)
14.5. Market Value Forecast, by Indication , 2017–2031
14.5.1. Musculoskeletal Diseases
14.5.2. Cardiovascular Diseases
14.5.3. Neuro Disorders
14.5.4. Autoimmune Diseases
14.5.5. Cancer
14.5.6. GvHD
14.5.7. Pulmonary Diseases
14.5.8. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Type
14.7.3. By Source of Isolation
14.7.4. By Indication
14.7.5. By Country/Sub-region
15. Middle East & Africa Mesenchymal Stem Cells Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Products & Services, 2017–2031
15.2.1. Product
15.2.1.1. Workflow Type
15.2.1.2. Product Type
15.2.2. Services
15.3. Market Value Forecast, by Type, 2017–2031
15.3.1. Autologous
15.3.2. Allogenic
15.4. Market Value Forecast, by Source of Isolation, 2017–2031
15.4.1. Bone Marrow
15.4.1.1. Adipose
15.4.1.2. Cord Blood
15.4.1.3. Peripheral Blood
15.4.2. Dental Pulp
15.4.3. Others (lung tissue, umbilical cord tissue, etc.)
15.5. Market Value Forecast, by Indication, 2017–2031
15.5.1. Musculoskeletal Diseases
15.5.2. Cardiovascular Diseases
15.5.3. Neuro Disorders
15.5.4. Autoimmune Diseases
15.5.5. Cancer
15.5.6. GvHD
15.5.7. Pulmonary Diseases
15.5.8. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Type
15.7.3. By Source of Isolation
15.7.4. By Indication
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Thermo Fisher Scientific, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Cytiva (Danaher Corporation)
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. FUJIFILM Irvine Scientific (FUJIFILM Corporation)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Merck KGaA
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Lonza Group Ltd.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. STEMCELL Technologies, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Takara Bio, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Sartorius AG
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Miltenyi Biotec GmbH
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. PromoCell GmbH
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
Table 01: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 02: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 03: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 04: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2032
Table 05: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 06: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Region, 2017–2032
Table 07: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country, 2017–2032
Table 08: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 09: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 10: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 11: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 12: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 13: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032
Table 14: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 15: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 16: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 17: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 18: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 19: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032
Table 20: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 21: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 22: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 23: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 24: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 25: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032
Table 26: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 27: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 28: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 29: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 30: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 31: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032
Table 32: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 33: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 34: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 35: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 36: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032